Pfizer scraps weight-loss pill after patient's liver injury
Pfizer (PFE) announced early Monday that it is halting a late-stage trial of its GLP-1 pill candidate, danuglipron, dashing hopes of the company entering the obesity space in the near term. A trial participant in the phase III trial of its once-daily pill …